Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma

Defining a role for systemic chemotherapy in local and advanced appendix adenocarcinoma

BACKGROUNDAppendix adenocarcinomas (AAs) are rare tumours that often present late, with a propensity for peritoneal metastases (PMs). This study aimed to evaluate outcomes of AA patients undergoing cytoreductive surgery (CRS) with curative intent and determine the role of systemic chemotherapy.MATER...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ESMO open 2023-10, Vol.8 (5), p.101619-101619, Article 101619
Hauptverfasser: Strach, M.C., Chakrabarty, B., Nagaraju, R.T., Mullamitha, S., Braun, M., O’Dwyer, S.T., Aziz, O., Barriuso, J.
Format: Artikel
Sprache:eng
Schlagworte:
Original Research
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUNDAppendix adenocarcinomas (AAs) are rare tumours that often present late, with a propensity for peritoneal metastases (PMs). This study aimed to evaluate outcomes of AA patients undergoing cytoreductive surgery (CRS) with curative intent and determine the role of systemic chemotherapy.MATERIALS AND METHODSData were collected from a prospective database and classified according to World Health Organization (WHO) 2019 classification. Tumour clearance from CRS was described using a completeness of cytoreduction (CC) score ranging from 0 [no residual disease (RD)] to 3 (>2.5 cm RD). Patients with CC0-2 CRS received hyperthermic intraperitoneal chemotherapy (HIPEC). Systemic chemotherapy was categorised as 'prior' (>6 months before), 'neoadjuvant' (
ISSN:2059-7029
2059-7029
DOI:10.1016/j.esmoop.2023.101619